Download PDF
Horm Metab Res 2010; 42: S56-S63
DOI: 10.1055/s-0029-1240976
Guidelines

© Georg Thieme Verlag KG Stuttgart · New York

Quality Indicators for the Prevention of Type 2 Diabetes in Europe – IMAGE

P. Pajunen1 , R. Landgraf2 , F. Muylle3 , A. Neumann4 , 5 , J. Lindström1 , P. E. Schwarz4 , M. Peltonen1 IMAGE Study Group: T. Acosta, M. Adler, A. AlKerwi, N. Barengo, R. Barengo, J. M. Boavida, K. Charlesworth, V. Christov, B. Claussen, X. Cos, E. Cosson, S. Deceukelier, V. Dimitrijevic-Sreckovic, P. Djordjevic, P. Evans, A.-M. Felton, M. Fischer, R. Gabriel-Sanchez, A. Gilis-Januszewska, M. Goldfracht, J. L. Gomez, C. J. Greaves, M. Hall, U. Handke, H. Hauner, J. Herbst, N. Hermanns, L. Herrebrugh, C. Huber, U. Hühmer, J. Huttunen, A. Jotic, Z. Kamenov, S. Karadeniz, N. Katsilambros, M. Khalangot, K. Kissimova-Skarbek, D. Köhler, V. Kopp, P. Kronsbein, B. Kulzer, D. Kyne-Grzebalski, K. Lalic, N. Lalic, R. Landgraf, Y. H. Lee-Barkey, S. Liatis, J. Lindström, K. Makrilakis, C. McIntosh, M. McKee, A. C. Mesquita, D. Misina, F. Muylle, A. Neumann, A. C. Paiva, P. Pajunen, B. Paulweber, M. Peltonen, L. Perrenoud, A. Pfeiffer, A. Pölönen, S. Puhl, F. Raposo, T. Reinehr, A. Rissanen, C. Robinson, M. Roden, U. Rothe, T. Saaristo, J. Scholl, P. E. Schwarz, K. E. Sheppard, S. Spiers, T. Stemper, B. Stratmann, J. Szendroedi, Z. Szybinski, T. Tankova, V. Telle-Hjellset, G. Terry, D. Tolks, F. Toti, J. Tuomilehto, A. Undeutsch, C. Valadas, P. Valensi, D. Velickiene, P. Vermunt, R. Weiss, J. Wens, T. Yilmaz
  • 1Diabetes Prevention Unit, Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland
  • 2German Diabetes Foundation, Munich, Germany
  • 3Vlaamse Diabetes Vereniging vzw, Gent, Belgium
  • 4Carl Gustav Carus Medical Faculty, Technical University of Dresden, Dresden, Germany
  • 5Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden
Further Information

Publication History

Publication Date:
13 April 2010 (online)

Also available at
   Permissions and Reprints

Abstract

Background: The marked increase of type 2 diabetes necessitates active development and implementation of efficient prevention programs. A European level action has been taken by launching the IMAGE project to unify and improve the various prevention management concepts, which currently exist within the EU. This report describes the background and the methods used in the development of the IMAGE project quality indicators for diabetes primary prevention programs. It is targeted to the persons responsible for diabetes prevention at different levels of the health care systems. Methods: Development of the quality indicators was conducted by a group of specialists representing different professional groups from several European countries. Indicators and measurement recommendations were produced by the expert group in consensus meetings and further developed by combining evidence and expert opinion. Results: The quality indicators were developed for different prevention strategies: population level prevention strategy, screening for high risk, and high risk prevention strategy. Totally, 22 quality indicators were generated. They constitute the minimum level of quality assurance recommended for diabetes prevention programs. In addition, 20 scientific evaluation indicators with measurement standards were produced. These micro level indicators describe measurements, which should be used if evaluation, reporting, and scientific analysis are planned. Conclusions: We hope that these quality tools together with the IMAGE guidelines will provide a useful tool for improving the quality of diabetes prevention in Europe and make different prevention approaches comparable.

References

  • 1 Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.  Diabetes Care. 2004;  27 1047-1053
    Google Scholar
  • 2 IDF .IDF Diabetes Atlas, 2009. [updated 2009; cited October 21, 2009] Available from:. http://www.diabetesatlas.org/
    PubMedGoogle Scholar
  • 3 Tuomilehto J, Lindström J, Eriksson J G, Valle T T, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.  N Engl J Med. 2001;  344 1343-1350
    CrossrefPubMedGoogle Scholar
  • 4 Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson J G, Hemio K, Hämäläinen H, Härkönen P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle T T, Uusitupa M, Tuomilehto J. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study.  Lancet. 2006;  368 1673-1679
    CrossrefPubMedGoogle Scholar
  • 5 Knowler W C, Barrett-Connor E, Fowler S E, Hamman R F, Lachin J M, Walker E A, Nathan D M. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.  N Engl J Med. 2002;  346 393-403
    CrossrefPubMedGoogle Scholar
  • 6 Li G, Zhang P, Wang J, Gregg E W, Yang W, Gong Q, Li H, Jiang Y, An Y, Shuai Y, Zhang B, Zhang J, Thompson T J, Gerzoff R B, Roglic G, Hu Y, Bennett P H. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study.  Lancet. 2008;  371 1783-1789
    CrossrefPubMedGoogle Scholar
  • 7 Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar A D, Vijay V. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1).  Diabetologia. 2006;  49 289-297
    CrossrefPubMedGoogle Scholar
  • 8 Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males.  Diabetes Res Clin Pract. 2005;  67 152-162
    CrossrefPubMedGoogle Scholar
  • 9 Schwarz P E, Schwarz J, Schuppenies A, Bornstein S R, Schulze J. Development of a diabetes prevention management program for clinical practice.  Public Health Rep. 2007;  122 258-263
    CrossrefPubMedGoogle Scholar
  • 10 Schwarz P E, Gruhl U, Bornstein S R, Landgraf R, Hall M, Tuomilehto J. The European perspective on diabetes prevention: development and Implementation of A European Guideline and training standards for diabetes prevention (IMAGE).  Diab Vasc Dis Res. 2007;  4 353-357
    CrossrefPubMedGoogle Scholar
  • 11 EUCID .Final report European Core Indicators in Diabetes project, 2008. [updated 2008; cited October 21, 2009] Available from:. http://ec.europa.eu/health/ph_projects/2005/action1/docs/action1_2005_frep_11_en.pdf
    PubMedGoogle Scholar
  • 12 Wens J, Dirven K, Mathieu C, Paulus D, Van Royen P. Quality indicators for type-2 diabetes care in practice guidelines: an example from six European countries.  Prim Care Diabetes. 2007;  1 17-23
    CrossrefPubMedGoogle Scholar
  • 13 IDF . Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care.  Diabet Med. 2006;  23 579-593
    CrossrefPubMedGoogle Scholar
  • 14 Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer M J, Cosentino F, Jonsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori S G, Blanc J J, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano J L, Deckers J W, Bertrand M, Charbonnel B, Erdmann E, Ferrannini E, Flyvbjerg A, Gohlke H, Juanatey J R, Graham I, Monteiro P F, Parhofer K, Pyorala K, Raz I, Schernthaner G, Volpe M, Wood D. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD).  Eur Heart J. 2007;  28 88-136
    CrossrefPubMedGoogle Scholar
  • 15 Buse J B, Ginsberg H N, Bakris G L, Clark N G, Costa F, Eckel R, Fonseca V, Gerstein H C, Grundy S, Nesto R W, Pignone M P, Plutzky J, Porte D, Redberg R, Stitzel K F, Stone N J. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association.  Circulation. 2007;  115 114-126
    PubMedGoogle Scholar
  • 16 Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori S G, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Op Reimer W S, Weissberg P, Wood D, Yarnell J, Zamorano J L, Walma E, Fitzgerald T, Cooney M T, Dudina A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I, Kristensen S D, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Altiner A, Bonora E, Durrington P N, Fagard R, Giampaoli S, Hemingway H, Hakansson J, Kjeldsen S E, Larsen L, Mancia G, Manolis A J, Orth-Gomer K, Pedersen T, Rayner M, Ryden L, Sammut M, Schneiderman N, Stalenhoef A F, Tokgozoglu L, Wiklund O, Zampelas A. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts).  Eur J Cardiovasc Prev Rehabil. 2007;  14 (Suppl. 2) S1-S113
    PubMedGoogle Scholar
  • 17 Greenfield S, Nicolucci A, Mattke S. Selecting indicators for the quality of diabetes care at the health system level in OECD countries. Paris; OECD Health Technical Papers 2004
    PubMedGoogle Scholar
  • 18 Nicolucci A, Greenfield S, Mattke S. Selecting indicators for the quality of diabetes care at the health systems level in OECD countries.  Int J Qual Health Care. 2006;  18 (Suppl. 1) 26-30
    CrossrefPubMedGoogle Scholar
  • 19 Fleming B B, Greenfield S, Engelgau M M, Pogach L M, Clauser S B, Parrott M A. The Diabetes Quality Improvement Project: moving science into health policy to gain an edge on the diabetes epidemic.  Diabetes Care. 2001;  24 1815-1820
    CrossrefPubMedGoogle Scholar
  • 20 de Beaufort C E, Reunanen A, Raleigh V, Storms F, Kleinebreil L, Gallego R, Giorda C, Midthjell K, Jecht M, de Leeuw I, Schober E, Boran G, Tolis G. European Union diabetes indicators: fact or fiction?.  Eur J Public Health. 2003;  13 51-54
    PubMedGoogle Scholar
  • 21 Rothe U, Muller G, Schwarz P E, Seifert M, Kunath H, Koch R, Bergmann S, Julius U, Bornstein S R, Hanefeld M, Schulze J. Evaluation of a diabetes management system based on practice guidelines, integrated care, and continuous quality management in a Federal State of Germany: a population-based approach to health care research.  Diabetes Care. 2008;  31 863-868
    CrossrefPubMedGoogle Scholar
  • 22 Martirosyan L, Braspenning J, Denig P, de Grauw W J, Bouma M, Storms F, Haaijer-Ruskamp F M. Prescribing quality indicators of type 2 diabetes mellitus ambulatory care.  Qual Saf Health Care. 2008;  17 318-323
    CrossrefPubMedGoogle Scholar
  • 23 Anonymous. Consensus statement on the worldwide standardisation of the HbA1c measurement.  Diabetologia. 2007;  50 2042-2043
    CrossrefPubMedGoogle Scholar
  • 24 Anonymous. Implementation of standardization of HbA1c measurement. Summary of the meeting with manufacturers held in Milan, Italy, December 12, 2007.  Clin Chem Lab Med. 2008;  46 573-574
    CrossrefPubMedGoogle Scholar
  • 25 Gillies C L, Abrams K R, Lambert P C, Cooper N J, Sutton A J, Hsu R T, Khunti K. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis.  BMJ. 2007;  334 299
    CrossrefPubMedGoogle Scholar
  • 26 Chiasson J L, Josse R G, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.  JAMA. 2003;  290 486-494
    CrossrefPubMedGoogle Scholar
  • 27 Richelsen B, Tonstad S, Rossner S, Toubro S, Niskanen L, Madsbad S, Mustajoki P, Rissanen A. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.  Diabetes Care. 2007;  30 27-32
    CrossrefPubMedGoogle Scholar
  • 28 Torgerson J S, Hauptman J, Boldrin M N, Sjöström L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.  Diabetes Care. 2004;  27 155-161
    Google Scholar
  • 29 Defronzo R A, Banerji M, Bray G A, Buchanan T A, Clement S, Henry R R, Kitabchi A E, Mudaliar S, Musi N, Ratner R, Reaven P D, Schwenke D, Stentz F B, Tripathy D. Actos Now for the prevention of diabetes (ACT NOW) study.  BMC Endocr Disord. 2009;  9 17
    CrossrefPubMedGoogle Scholar
  • 30 Donabedian A. Evaluating the quality of medical care.  Milbank Mem Fund Q. 1966;  44 (Suppl.) 166-206
    CrossrefPubMedGoogle Scholar
  • 31 Donabedian A. The quality of care. How can it be assessed?.  JAMA. 1988;  260 1743-1748
    CrossrefPubMedGoogle Scholar
  • 32 Mainz J. Developing evidence-based clinical indicators: a state of the art methods primer.  Int J Qual Health Care. 2003;  15 (Suppl. 1) i5-i11
    CrossrefPubMedGoogle Scholar
  • 33 Bruns D E, Knowler W C. Stabilization of glucose in blood samples: why it matters.  Clin Chem. 2009;  55 850-852
    CrossrefPubMedGoogle Scholar
  • 34 Gambino R, Piscitelli J, Ackattupathil T A, Theriault J L, Andrin R D, Sanfilippo M L, Etienne M. Acidification of blood is superior to sodium fluoride alone as an inhibitor of glycolysis.  Clin Chem. 2009;  55 1019-1021
    CrossrefPubMedGoogle Scholar
  • 35 Kriska A, Caspersen C. Introduction to a collection of physical activity questionnaires.  Med Sci Sports Exerc. 1997;  29 (Suppl. 6) S5-S9
    PubMedGoogle Scholar
  • 36 Feasibility of a European Health Examination Survey (FEHES) project. [cited November 3, 2009] Available from:. http://www.ktl.fi/fehes/
    Google Scholar
  • 37 EUBIROD. EUropean Best Information through Regional Outcomes in Diabetes. [cited October 27, 2009] Available from:. http://www.eubirod.eu/home.htm
    Google Scholar
  • 38 Tolonen H, Koponen P, Aromaa A, Conti S, Graff-Iversen S, Grotvedt L, Kanieff M, Mindell J, Natunen S, Kuulasmaa K. for the feasibility of a European Health Examination Survey (FEHES) Project .Recommendations for the Health Examination Surveys in Europe, 2009. [updated 2009; cited October 21, 2009] Available from:. http://www.ktl.fi/attachments/suomi/julkaisut/julkaisusarja_b/2008/2008b21.pdf
    PubMedGoogle Scholar
  • 39 WHO .STEPwise approach to surveillance (STEPS). Part 3: Training and Practical Guides 3-3-14. Section 3: Guide to Physical Measurements (Step 2) 2008. [updated 2008; cited October 21, 2009] Available from:. http://www.who.int/chp/steps/Part3_Section3.pdf
    PubMedGoogle Scholar
  • 40 WHO .Laboratory Diagnosis and Monitoring of Diabetes Mellitus 2002. [updated 2002; cited October 21, 2009] Available from:. http://whqlibdoc.who.int/hq/2002/9241590483.pdf
    PubMedGoogle Scholar
  • 41 IFCC .Standardization of Insulin Assays (WG-SIA), in collaboration with ADA/EASD. [cited October 21, 2009] Available from:. http://ifcc.nassaro.com/index.asp?cat=Scientific_Activities&scat=Working_Groups&suba=Standardization_of_Insulin_Assays_%2528WG-SIA%2529&zip=1&dove=1&numero=70
    PubMedGoogle Scholar
  • 42 Block G. Human dietary assessment: methods and issues.  Prev Med. 1989;  18 653-660
    CrossrefPubMedGoogle Scholar
  • 43 Willett W. Nutritional epidemiology, 2nd edition. New York; Oxford University Press 1998
    PubMedGoogle Scholar
  • 44 Paffenbarger Jr R S, Blair S N, Lee I M, Hyde R T. Measurement of physical activity to assess health effects in free-living populations.  Med Sci Sports Exerc. 1993;  25 60-70
    PubMedGoogle Scholar
  • 45 Lakka T A, Salonen J T. Intra-person variability of various physical activity assessments in the Kuopio Ischaemic Heart Disease Risk Factor Study.  Int J Epidemiol. 1992;  21 467-472
    CrossrefPubMedGoogle Scholar
  • 46 Lakka T A, Venöläinen J M, Rauramaa R, Salonen R, Tuomilehto J, Salonen J T. Relation of leisure-time physical activity and cardiorespiratory fitness to the risk of acute myocardial infarction.  N Engl J Med. 1994;  330 1549-1554
    CrossrefPubMedGoogle Scholar
  • 47 Lindström J, Louheranta A, Mannelin M, Rastas M, Salminen V, Eriksson J, Uusitupa M, Tuomilehto J. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity.  Diabetes Care. 2003;  26 3230-3236
    CrossrefPubMedGoogle Scholar
  • 48 IPAQ .The International Physical Activity Questionnaires (IPAQ). [cited October 21, 2009] Available from:. http://www.ipaq.ki.se/ipaq.htm
    PubMedGoogle Scholar
  • 49 CDC .The Cholesterol Reference Method Laboratory Network (CRMLN). [cited October 21, 2009] Available from:. http://www.cdc.gov/labstandards/crmln.htm
    PubMedGoogle Scholar
  • 50 EHIS .European Health Interview Survey (EHIS) Questionnaire 2006. [updated 2006; cited October 21, 2009] Available from:. http://ec.europa.eu/health/ph_information/implement/wp/systems/docs/ev_20070315_ehis_en.pdf
    PubMedGoogle Scholar
  • 51 WHO .WHO-Five Well-being Index (WHO-5). [cited October 21, 2009] Available from:. http://www.who-5.org/
    PubMedGoogle Scholar
  • 52 RAND .MOS 36-Item Short Form Survey Instrument (SF-36). [cited October 21, 2009] Available from:. http://www.rand.org/health/surveys_tools/mos/mos_core_36item.html
    PubMedGoogle Scholar
  • 53 RAND .Medical Outcomes Study: 12-Item Short Form Survey. [cited November 30, 2009] Available from:. http://www.rand.org/health/surveys_tools/mos/mos_core_12item.html
    PubMedGoogle Scholar
  • 54 Sintonen H. 15-D instrument. [cited October 21, 2009] Available from:. http://www.15d-instrument.net/15d
    PubMedGoogle Scholar
  • 55 Bradley C. The Diabetes Treatment Satisfaction Questionnaire: DTSQ. Bradley C Handbook of psychology and diabetes: a guide to psychological measurement in diabetes research and practice. Chur, Switzerland; Harwood Academic Publishers 1994: 111-132
    PubMedGoogle Scholar

Pia Pajunen

National Institute for Health and Welfare (THL)

P. O. Box 30

00271 Helsinki

Finland

Phone: + 35 82 06 10 60 00

Fax: + 35 82 06 10 86 61

Email: pia.pajunen@thl.fi

      >